Inventaire - your friends and communities are your best library

Pharmacokinetics and Pharmacodynamics of Pegylated Interferon Lambda-1 in Cynomolgus Monkeys

Author

Kelly Byrnes-Blake

Published in: Journal of Interferon and Cytokine Research

Date of publication: January 26, 2012

Language: English

Main subject: pegylated interferon, pharmacodynamics, pharmacokinetics

Bibliographic databases:

Cites articles 35

Date

Title

Authors

September 12, 1957

Virus interference. I. The interferon
July 1, 1984

Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma
October 1, 1986

Comparison of pharmacokinetic behaviors of two human interferons (Lb-IFN-alpha and Re-IFN-alpha A) in cynomolgus monkeys by 2'-5' oligoadenylate synthetase assay
1987

Interferons and their actions
July 1, 1993

Physiological parameters in laboratory animals and humans
August 1, 1996

The type-I interferon receptor. The long and short of it.
February 1, 1997

Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans
January 1, 1997

Interferons in host defense
November 1, 1999

PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases
May 1, 2000

Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes
April 1, 2000

Role of the cytoplasmic domains of the type I interferon receptor subunits in signaling
May 1, 2001

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.
June 1, 2002

The family of IL-10-related cytokines and their receptors: related, but to what extent?
November 1, 2002

Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys
September 1, 2003

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates
January 2003

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

, ,
January 2003

IL-28, IL-29 and their class II cytokine receptor IL-28R
January 1, 2003

An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates
August 2004

The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain

,
July 30, 2004

Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling

, ,
December 2004

Interferons, interferon-like cytokines, and their receptors
January 1, 2005

Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys
May 1, 2006

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

, ,
October 1, 2006

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes
October 1, 2006

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

, ,
May 14, 2007

The interferons: 50 years after their discovery, there is much more to learn
May 16, 2007

Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases

,
April 24, 2008

IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity
March 14, 2008

IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo
December 1, 2009

Interferon lambda as a potential new therapeutic for hepatitis C.
October 1, 2009

Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines

,
January 1, 2010

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b

Article -

Welcome to inventaire

The library of your friends and communities

Learn more